

TAK-024

Catalog No: tcsc0018405



Available Sizes

Size: 1mg

Size: 5mg

Size: 10mg



Specifications

CAS No:

186971-69-7

Formula:

$C_{27}H_{34}N_{10}O_6$

Pathway:

GPCR/G Protein

Target:

P2Y Receptor

Purity / Grade:

>98%

Solubility:

10 mM in DMSO

Observed Molecular Weight:

594.62

Product Description


TAK-024 is a **platelet** inhibitor with **IC₅₀**s of 31, 79 and 51 nM in human, monkey and guinea pig, respectively.

IC50 & Target: IC50: 31 nM (human platelet), 79 nM (monkey platelet), 51 nM (pig platelet)^[1]

In Vitro:

TAK-024 is a platelet inhibitor with IC_{50} s of 31, 79 and 51 nM in human, monkey and guinea pig, respectively. In a preliminary experiment, the IC_{50} value of TAK-024 in the heparinized blood sample is 230 nM, 4.5-fold less potent than that in the citrated physiological blood sample. The ID_{50} value of TAK-024 on *ex vivo* ADP-induced platelet aggregation in guinea pigs is 0.18 μ g/kg/min, the dissociation ratio of TAK-024 is found to be 32^[1].

In Vivo: Intravenous infusion of TAK-024 (compound 12c) at 1.6 μ g/mL/min completely prevents arterial thrombus formation induced by endothelial injury in guinea pigs. Results demonstrate the inhibitory effects of TAK-024 on the carotid thrombosis induced by balloon injury in guinea pigs and the ID_{50} value is 0.73 μ g/kg/min. A single dose of TAK-024 at 100 μ g/kg iv produces almost complete inhibition for 120 min, and about 40% inhibition is observed after 240 min. Dose-dependent inhibition of platelet aggregation is achieved with a single iv dose of 30 to 100 μ g/kg of TAK-024^[1].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!